HIV Testing Updates and Challenges: When Regulatory Caution and Public Health Imperatives Collide

Current HIV/AIDS Reports

Volumn 12, Issue 1, 2015, Pages 117-126

  Branson, Bernard M ^a  

^a Scientific Affairs LLC   (United States)

Author keywords

Acute HIV infection; FDA regulation; HIV diagnosis; HIV tests

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; VIRUS RNA;

ENZYME IMMUNOASSAY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; NUCLEIC ACID AMPLIFICATION; POINT OF CARE TESTING; PUBLIC HEALTH; REVIEW; UNITED STATES; VIRAL LOAD TESTING; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; FOOD AND DRUG ADMINISTRATION; HIV INFECTIONS; LEGISLATION AND JURISPRUDENCE; PROCEDURES; TRENDS;

CLINICAL LABORATORY TECHNIQUES; EARLY DIAGNOSIS; HIV INFECTIONS; HUMANS; PUBLIC HEALTH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84925503896     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-014-0251-7     Document Type: Review

References (95)

1. Centers for Disease Control and Prevention, Association of Public Health Laboratories. Laboratory testing for the diagnosis of HIV infection: updated recommendations. 2014:1-66. http://stacks.cdc.gov/view/cdc/23447. Accessed 09/20/2014. A comprehensive summary of HIV diagnostic testing technology and evidence for recommendations for the updated laboratory testing algorithm.
2. Centers for Disease Control and Prevention. Notice to readers: approval of a new rapid test for HIV antibody. MMWR Morb Mortal Wkly Rep. 2002;51:1051–2.
3. O’Rourke M, Branson B, del Rio C, Larrabee S, Sax PE. Rapid fingerstick testing: a new era in HIV diagnostics. AIDS Clin Care. 2003;15:19–23,30.
4. Hutchinson AB, Branson BM, Kim A, Farnham PG. A meta-analysis of the effectiveness of alternative HIV counseling and testing methods to increase knowledge of HIV status. AIDS. 2006;20:1597–604.
5. CDC. Protocols for confirmation of rapid HIV tests. MMWR Morb Mortal Wkly Rep. 2004;53:221–2.
6. Shah D, Chang C, Cheng K, Wachter A, Stewart J. Combined HIV antigen and antibody assay on a fully automated chemiluminescence based analyzer. 11th International Symposium on Bioluminescence and Chemiluminescence. Pacific Grove, CA: World Scientific Publishing Co. Pte. Ltd.; 2000:365-368.
7. Ortho Diagnostics. VITROS Immunodiagnostic Products, Anti-HIV 1+2 Reagent Pack [product insert]. 2008. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/ucm092018.pdf. Accessed July 14, 2013.
8. Siemens Healthcare. HIV 1/O/2 Enhanced (EHIV) [product insert]. 2006; http://www.fda.gov/downloads/Biologicsbloodvaccines/Bloodbloodproducts/Approvedproducts/PremarketApprovalsPMAs/UCM091286.pdf. Accessed July 12, 2013.
9. Abbott. Architect HIV Ag/Ab Combo [product insert]. 2010; http://www.abbottdiagnostics.com/Support/Technical_Library/Package_Inserts/getPIFile.cfm?controlNumber=345589. Accessed April 23, 2012.
10. Bio-Rad. GS HIV Combo Ag/Ab EIA [product insert]. 2011; http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/UCM266211.pdf. Accessed April 23, 2012.
11. Salmona M, Delarue S, Delaugerre C, Simon F, Maylin S. Clinical evaluation of BioPlex 2200 HIV Ag-Ab, an automated screening method providing discrete detection of HIV-1 p24 antigen, HIV-1 antibody, and HIV-2 antibody. J Clin Microbiol. 2014;52:103–7.
12. Branson BM. Rapid tests for HIV antibody. AIDS Rev. 2000; 76-83.
13. Owen SM, Yang C, Spira T, et al. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol. 2008;46:1588–95.
14. Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, Owen SM. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol. 2011;52 Suppl 1:S17–22. Summarizes a comparison of the seroconversion sensitivity of FDA-approved HIV diagnostic tests and provides an example of a head-to-head comparison of different assays on the same challenge panel of specimens.
15. Alere Inc. Alere Determine HIV 1/2 Ag/Ab Combo [product insert]. 2013; http://www.alere.com/content/alere/us/en/product-details/determine-1-2-ag-ab-combo-us.html.html. Accessed October 30, 2014.
16. Chembio Diagnostic Systems Inc. DPP HIV 1/2 Assay [product insert]. 2012; http://chembio.com/wp-content/uploads/2013/04/10-6273-0-Product-Insert-DPP-HIV-Rev-8.pdf. Accessed October 15, 2014.
17. Food and Drug Administration (FDA). October 24, 2014 Approval Letter - Geenius HIV 1/2 Supplemental Assay 2014; http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/ucm420751.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Accessed November 1, 2014.
18. Delaney KP, Branson BM, Uniyal A, et al. Performance of an oral fluid rapid HIV 1/2 test: experience from four CDC studies. AIDS. 2006;20:1655–60.
19. Centers for Disease Control and Prevention. False-positive oral fluid rapid HIV tests--New York City, 2005-2008. MMWR Morb Mortal Wkly Rep. 2008;57:660–5.
20. O’Connell RJ, Merritt TM, Malia JA, et al. Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol. 2003;41:2153–5.
21. Stekler JD, O’Neal JD, Lane A, et al. Relative accuracy of serum, whole blood, and oral fluid HIV tests among Seattle men who have sex with men. J ClinVirol. 2013;58 Suppl 1:e19–22. Prospective clinical study among a frequently tested population with high HIV incidence comparing the accuracy of different HIV tests when performed on different types of specimens.
22. Stekler JD, Swenson PD, Coombs RW, et al. HIV testing in a high-incidence population: is antibody testing alone good enough? Clin Infect Dis. 2009;49:444–53.
23. Luo W, Masciotra S, Delaney KP, et al. Comparison of HIV oral fluid and plasma antibody results during early infection in a longitudinal Nigerian cohort. J Clin Virol. 2013;58 Suppl 1:e113–118. Study comparing sensitivity of oral fluid and serum specimens that were prospectively collected at frequent interval from recent seroconverters.
24. Gen-Probe. Aptima® HIV-1 RNA qualitative assay [product insert]. 2009; http://www.gen-probe.com/pdfs/pi/501623RevA.pdf. Accessed February 4, 2011.
25. Ritchie AV, Ushiro-Lumb I, Edemaga D, et al. SAMBA HIV semiquantitative test, a new point-of-care viral-load-monitoring assay for resource-limited settings. J Clin Microbiol. 2014;52:3377–83.
26. Tanriverdi S, Chen L, Chen S. A rapid and automated sample-to-result HIV load test for near-patient application. J Infect Dis. 2010;201 Suppl 1:S52–58.
27. Cohen MS, Dye C, Fraser C, Miller WC, Powers KA, Williams BG. HIV treatment as prevention: debate and commentary—will early infection compromise treatment-as-prevention strategies? PLoS Med. 2012;9:e1001232.
28. Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. J Infect Dis. 2010;202 Suppl 2:S270–277.
29. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med. 2011;364:1943–54. Summary article describing pathogenesis during acute HIV-1 infection and its importance for the subsequent clinical course of HIV disease and implications for enhanced HIV transmission.
30. Pilcher CD, Tien HC, Eron JJ, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004;189:1785–92.
31. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis. 2006;194:725–33.
32. Hamlyn E, Jones V, Porter K, Fidler S. Antiretroviral treatment of primary HIV infection to reduce onward transmission. Curr Opin HIV AIDS. 2010;5:283–90.
33. Hogan CM, Degruttola V, Sun X, et al. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis. 2012;205:87–96.
34. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2013. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed June 10, 2013.
35. Hocqueloux L, Saez-Cirion A, Rouzioux C. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. JAMA Intern Med. 2013;173:475–6.
36. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9:e1003211.
37. Smith MK, Rutstein SE, Powers KA, et al. The detection and management of early HIV infection: a clinical and public health emergency. J Acquir Immune Defic Syndr. 2013;63 Suppl 2:S187–199.
38. Pilcher CD, Joaki G, Hoffman IF, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS. 2007;21:1723–30.
39. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis. 2008;198:687–93.
40. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis. 2007;195:951–9.
41. Pilcher CD, Christopoulos KA, Golden M. Public health rationale for rapid nucleic acid or p24 antigen tests for HIV. J Infect Dis. 2010;201 Suppl 1:S7–15.
42. Centers for Disease Control (CDC). Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR Morb Mortal Wkly Rep. 1989;38:1–7.
43. Centers for Disease Control and Prevention (CDC). Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm—United States, 2011-2013. MMWR Morb Mortal Wkly Rep. 2013;62:489–94. Description of two evaluation of the updated HIV testing recommendations demonstrating the ability to detect acute HIV-1 infections and the high viral load observed in acute-stage patients.
44. Eshleman SH, Khaki L, Laeyendecker O, et al. Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab combo assay. J Acquir Immune Defic Syndr. 2009;52:121–4.
45. Linley L, Ethridge SF, Oraka E, et al. Evaluation of supplemental testing with the Multispot HIV-1/HIV-2 rapid test and APTIMA HIV-1 RNA qualitative assay to resolve specimens with indeterminate or negative HIV-1 Western blots. J Clin Virol. 2013;58 Suppl 1:e108–112.
46. New York Department of Health and Mental Hygiene. 2012 HEALTH ADVISORY #29: missed opportunity to detect acute HIV infection. 2012. http://www.nyc.gov/html/doh/downloads/pdf/cd/2012/12md29.pdf. Accessed 3/29/2013.
47. Pandori MW, Hackett Jr J, Louie B, et al. Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J Clin Microbiol. 2009;47:2639–42.
48. Patel P, Mackellar D, Simmons P, et al. Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008. Arch Intern Med. 2010;170:66–74.
49. Pilcher CD, Louie B, Facente S, et al. Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco. PLoS One. 2013;8:e80629.
50. CDC. HIV-2 infection surveillance—United States, 1987-2009. MMWR Morb Mortal Wkly Rep. 2011;60:985–8.
51. Torian LV, Eavey JJ, Punsalang AP, et al. HIV type 2 in New York City, 2000-2008. Clin Infect Dis. 2010;51:1334–42.
52. Nasrullah M, Ethridge SF, Delaney KP, et al. Comparison of alternative interpretive criteria for the HIV-1 Western blot and results of the Multispot HIV-1/HIV-2 rapid test for classifying HIV-1 and HIV-2 infections. J Clin Virol. 2011;52 Suppl 1:S23–27.
53. Ntemgwa ML, d’Aquin TT, Brenner BG, RJ C, Wainberg MA. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother. 2009;53:3611–9.
54. Hizi A, Tal R, Shaharabany M, et al. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob Agents Chemother. 1993;37:1037–42.
55. Westheimer E, Fu J, Radix A, et al. An HIV-1 RNA test following a reactive fourth-generation antigen/antibody combination assay confirms a high proportion of HIV infections. J ClinVirol. 2014. http://www.journalofclinicalvirology.com/article/S1386-6532(14)00397-7/pdf. Accessed November 1, 2014. Comparison of the HIV-1 Western blot, Multispot HIV-1/HIV-2 Antibody Differentiation Assay, and APTIMA qualitative RNA assay for confirmation of HIV infection in prospectively collected specimens with a reactive combination antigen/antibody immunoassay.
56. Ethridge SF, Wesolowski LG, Nasrullah M, et al. Comparative evaluation of Aptima HIV-1 Qualitative RNA assay performance using plasma and serum specimens from persons with established HIV-1 infection. J Clin Virol. 2011;52 Suppl 1:S63–66.
57. Ren A, Louie B, Rauch L, et al. Screening and confirmation of human immunodeficiency virus type 1 infection solely by detection of RNA. J Med Microbiol. 2008;57:1228–33.
58. Murphy G, Aitken C. HIV testing—the perspective from across the pond. J Clin Virol. 2011;52 Suppl 1:S71–76.
59. Jurriaans S, Back NK, Wolthers KC. Ten years of HIV testing with fourth generation assays: the Amsterdam experience. J Clin Virol. 2011;52 Suppl 1:S67–69.
60. CDC. Acute HIV infection—New York City, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:1296–9.
61. Mansfield E, O’Leary TJ, Gutman SI. Food and Drug Administration regulation of in vitro diagnostic devices. J Mol Diagn. 2005;7:2–7.
62. Food and Drug Administration (FDA). Medical device user fees for fiscal year 2015 2014; http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/ucm407660.htm. Accessed December 3, 2014.
63. Commission of the European Communities. Common technical specifications for in vitro diagnostic medical devices. 2009; http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2002D0364:20091201:EN:PDF. Accessed December 2, 2014.
64. Food and Drug Administration (FDA). Transcript of the 59th Blood Products Advisory Committee meeting. 1998; www.fda.gov/ohrms/dockets/ac/98/transcpt/3431t1.rtf. Accessed December 2, 2014.
65. Food and Drug Administration (FDA). Summary of safety and effectiveness, OraQuick In-Home HIV Tst. 2012; http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/UCM312534.pdf. Accessed November 20, 2014.
66. Myers JE, El-Sadr WM, Zerbe A, Branson BM. Rapid HIV self-testing: long in coming but opportunities beckon. AIDS. 2013;27:1687–5.
67. Centers for Disease Control and Prevention (CDC). HIV surveillance report, 2012. 2014; http://www.cdc.gov/hiv/library/reports/surveillance/2012/surveillance_Report_vol_24.html. Accessed December 1, 2014.
68. Busch MP, Courouce AM. Relative sensitivity of United States and European assays for screening blood donors for antibodies to human immunodeficiency viruses. Transfusion. 1997;37:352–4.
69. Code of Federal Regulations, Title 42. Vol 5, Section 493.15. Washington, DC 2013.
70. Lusky K. Rapid HIV tests a weather vane for waived tests. CAP Today. 2004. http://www.captodayonline.com/Archives/feature_stories/0404RapidHIV.html. Accessed October 20, 2014
71. Howerton D, Anderson N, Bosse D, Granade S, Westbrook G. Good laboratory practices for waived testing sites: survey findings from testing sites holding a certificate of waiver under the clinical laboratory improvement amendments of 1988 and recommendations for promoting quality testing. MMWR Recomm Rep. 2005;54:1–25.
72. Food and Drug Administration (FDA). Guidance for industry and FDA staff: recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver applications for manufacturers of in vitro diagnostic devices. 2008. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070890.pdf. Accessed October 22, 2014.
73. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17.
74. Centers for Medicare and Medicaid Services (CMS). Standard: establishment and verification of performance specifications. 2008; 42 CFR 5 § 493.1253.
75. Lilian RR, Bhowan K, Sherman GG. Early diagnosis of human immunodeficiency virus-1 infection in infants with the NucliSens EasyQ assay on dried blood spots. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2010;48:40–3.
76. Parry JV, Mortimer PP, Nicoll AG. Performance assessment of neonatal dried blood spot testing for HIV antibody. Commun Dis Rep CDR Rev. 1992;2:R128–130.
77. Smit PW, Sollis KA, Fiscus S, et al. Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. PLoS One. 2014;9:e86461.
78. Sullivan TJ, Antonio-Gaddy MS, Richardson-Moore A, Styer LM, Bigelow-Saulsbery D, Parker MM. Expansion of HIV screening to non-clinical venues is aided by the use of dried blood spots for Western blot confirmation. J Clin Virol. 2013;58 Suppl 1:e123–126.
79. Cardenas AM, Baughan E, Hodinka RL. Evaluation of the Bio-Rad Multispot HIV-1/HIV-2 rapid test as an alternative to Western blot for confirmation of HIV infection. J Clin Virol. 2013;58 Suppl 1:e97–e103.
80. Pandori MW, Westheimer E, Gay C, et al. The Multispot rapid HIV-1/HIV-2 differentiation assay is comparable with the Western blot and an immunofluorescence assay at confirming HIV infection in a prospective study in three regions of the United States. J Clin Virol. 2013;58 Suppl 1:e92–96.
81. Ramos EM, Harb S, Dragavon J, Coombs RW. Clinical performance of the Multispot HIV-1/HIV-2 rapid test to correctly differentiate HIV-2 from HIV-1 infection in screening algorithms using third and fourth generation assays and to identify cross reactivity with the HIV-1 Western Blot. J Clin Virol. 2013;58 Suppl 1:e104–107.
82. Styer LM, Sullivan TJ, Parker MM. Evaluation of an alternative supplemental testing strategy for HIV diagnosis by retrospective analysis of clinical HIV testing data. J Clin Virol. 2011;52 Suppl 1:S35–40.
83. Torian LV, Forgione LA, Punsalang AE, Pirillo RE, Oleszko WR. Comparison of Multispot EIA with Western blot for confirmatory serodiagnosis of HIV. J Clin Virol. 2011;52 Suppl 1:S41–44.
84. Food and Drug Administration (FDA). March 25, 2013 Supplement letter—Multispot HIV-1/HIV-2 rapid test. 2013; http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/ucm357028.htm. Accessed August 30, 2013.
85. Masciotra S, Luo W, Youngpairoj AS, et al. Performance of the Alere determine HIV-1/2 Ag/Ab combo rapid test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast. J Clin Virol. 2013;58 Suppl 1:e54–58.
86. Malloch L, Kadivar K, Putz J, et al. Comparative evaluation of the Bio-Rad Geenius HIV-1/2 confirmatory assay and the Bio-Rad Multispot HIV-1/2 rapid test as an alternative differentiation assay for CLSI M53 algorithm I. J Clin Virol. 2013;58 Suppl 1:e85–91.
87. Montesinos I, Eykmans J, Delforge ML. Evaluation of the Bio-Rad Geenius HIV-1/2 test as a confirmatory assay. J Clin Virol. 2014;60:399–401.
88. Hsu J, Brozek JL, Terracciano L, et al. Application of GRADE: making evidence-based recommendations about diagnostic tests in clinical practice guidelines. Implement Sci. 2011;6:62.
89. Ly TD, Ebel A, Faucher V, Fihman V, Laperche S. Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays? J Virol Methods. 2007;143:86–94.
90. Laperche S, Leballais L, Ly TD, Plantier JC. Failures in the detection of HIV p24 antigen with the determine HIV-1/2 Ag/Ab combo rapid test. J Infect Dis. 2012;206:1946–7. author reply 1949-1950.
91. Laperche S, Morel P, Deschaseaux M, et al. HIV antibody screening remains indispensable for ensuring viral safety of blood components despite NAT implementation. Transfusion. 2003;43:1428–32.
92. Food and Drug Administration (FDA). FDA proposes lower risk classification for certain tuberculosis tests. 2012; http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm296308.htm. Accessed December 12, 2014.
93. Branson BM. Home sample collection tests for HIV infection. JAMA. 1998;280:1699–701.
94. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med. 1997;102(5B):117–24.
95. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871–9.